THE PBS listing of Jardiance (empagliflozin 10mg and 25mg) has been expanded to allow use right from the start with metformin in patients with type 2 diabetes (T2D) who are at high cardiovascular (CV) risk, have existing CV disease, or identify as Aboriginal or Torres Strait Islander - regardless of their HbA1c level.
More than 115,000 additional Australians are now eligible for treatment with the drug.
"Jardiance was the first SGLT-2 inhibitor shown to provide significant cardioprotective benefits and remains the only medicine in this class indicated to reduce the risk of cardiovascular death in patients with T2D and established CV disease," said Dr Ted Wu, Director of the Royal Prince Alfred Hospital Diabetes Centre.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Apr 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Apr 25
